Filing and reporting period
Issuer mismatch: The supplied filing is Access Pharmaceuticals, Inc.’s Form 10-K, not a filing for Abeona Therapeutics, Inc. It covers the fiscal year ended December 31, 2011; it does not provide standalone fourth-quarter financial results.
Access was an emerging biopharmaceutical company with one marketed product, MuGard, two Phase 2 candidates, ProLindac and Thiarabine, and several preclinical programs. Its strategy relied on product partners, licensing, and external financing.
Financial performance and position
| Metric | 2011 | 2010 |
|---|---|---|
| Total revenue | $1.848 million | $0.481 million |
| Operating expenses | $9.724 million | $8.238 million |
| Loss from operations | $7.876 million | $7.757 million |
| Net loss | $2.532 million | $7.537 million |
| Net loss attributable to common stockholders | $4.306 million | $9.328 million |
| Operating cash flow | $(7.609) million | $(6.860) million |
| Cash and cash equivalents at year-end | $2.460 million | $7.033 million |
- Revenue comprised $1.181 million in licensing, $548,000 in U.S. MuGard sales, $89,000 in European royalties, and $30,000 in sponsored research. Licensing revenue included recognition of $849,000 in previously deferred fees after the company regained licenses from its former Korean partner.
- MuGard product costs were $1.216 million against $548,000 of product sales, indicating product sales did not cover reported product costs. The filing does not provide a consolidated gross margin measure.
- Operating expenses increased $1.486 million, led by higher R&D spending ($4.200 million versus $3.349 million) and product costs; general and administrative expense decreased to $4.075 million from $4.511 million.
- The lower net loss reflected, among other items, changes in noncash derivative valuations and negotiated-payables income. In 2010, the company also recorded $1.479 million in one-time federal grant income. These items make the year-over-year net-loss comparison less indicative of operating performance.
- At December 31, 2011, total assets were $3.785 million and total liabilities were $21.391 million; stockholders’ deficit was $17.606 million. Working capital deficit was $8.877 million, versus $6.136 million a year earlier.
- Cash burn was reported at approximately $602,000 per month for 2011. Management projected approximately $469,000 per month from operations for the next 12 months. The filing’s stated operating runway was into the third quarter of 2012.
- A $2.750 million secured note remained outstanding, due September 13, 2012, with 12% annual interest. The company repaid $2.750 million in November 2011 and raised approximately $5.826 million net from November equity placements.
Material changes and business developments
- U.S. MuGard sales rose from $8,000 to $548,000 after its fourth-quarter 2010 launch; the filing says prescriptions were growing quarterly but does not provide prescription counts or sales guidance.
- MuGard had launched in several European markets, and Chinese regulatory and marketing approval was announced in March 2012. These developments post-date the reporting year.
- ProLindac combination studies were underway: one with paclitaxel in platinum-pretreated ovarian cancer and another with gemcitabine in cholangiocarcinoma. Thiarabine Phase 2 work in adult leukemia indications was underway at MD Anderson.
- November 2011 equity financings raised approximately $6.2 million gross and included warrants. The issuance also reset the conversion price of Series A preferred stock to $1.45 per share and repriced certain warrants.
- As of March 23, 2012, 2,938.3617 preferred shares were convertible into approximately 20.265 million common shares, in addition to 24.135 million common shares outstanding. Preferred stock carries a 6% dividend and rights senior to common stock.
Outlook, risks, and unusual items
- The independent auditor cited substantial doubt about the company’s ability to continue as a going concern. Management said existing resources and expected receipts would fund current operations only into the third quarter of 2012 and that additional financing was needed.
- Management intended to seek equity financing, licensing, or an extension of the secured note. Failure to obtain financing or extend the note could jeopardize operations; equity issuance could materially dilute existing holders.
- The company reported a material weakness in internal control over financial reporting, related to inadequate monitoring and review of the CFO’s work, limited accounting staff, and lack of segregation of duties. Management concluded disclosure controls and internal controls were not effective at year-end.
- Clinical, regulatory, manufacturing, reimbursement, partner-performance, intellectual-property, and competitive risks could delay or prevent commercialization. The filing states it did not expect significant near-term revenue and did not provide quantified product-sales guidance.
- Potential liquidated damages related to registration rights were accrued at $857,000; payment may not be required if the relevant shares are freely saleable under Rule 144. Preferred dividends payable totaled $6.487 million, plus interest.
- Reported earnings include substantial noncash derivative gains: $3.580 million for warrant liabilities and $1.410 million for preferred-stock derivatives in 2011. Results are sensitive to valuation assumptions and stock-price movements.
Investor verification points
- Confirm issuer identity: this document is for Access Pharmaceuticals, not Abeona Therapeutics.
- Verify current cash runway, financing plans, and the status or repayment of the $2.750 million secured note due September 2012.
- Assess MuGard sales, product costs, reimbursement coverage, and whether post-filing Chinese approval translated into commercial orders.
- Review trial enrollment, results, funding, and next milestones for ProLindac and Thiarabine.
- Quantify potential dilution from preferred-stock conversion, outstanding warrants, and future financing; confirm preferred dividends and registration-rights exposure.
- Track remediation of the disclosed material weakness and any subsequent auditor or management updates on going concern.